Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.
about
Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future DirectionsDiagnosis and Treatment of Leptomeningeal Metastasis in Non-small Cell Lung CancerProlonged response of meningeal carcinomatosis from non-small cell lung cancer to salvage intrathecal etoposide subsequent to failure of first-line methotrexate: a case report and literature reviewConcurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature.Nasogastric tube-administered alectinib achieved long-term survival in a crizotinib-refractory nonsmall cell lung cancer patient with a poor performance statusEfficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer.Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib.Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: A pooled analysisRapid Response to High-Dose, Pulsatile Erlotinib in Afatinib-Refractory Leptomeningeal Carcinomatosis from Adenocarcinoma of the Lung: A Case Report.Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance.State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer.Clinical Presentation, Diagnosis, and Radiological Findings of Neoplastic Meningitis.Neoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases.Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation.Bilateral Facial Nerve Paralysis as First Presentation of Lung Cancer.Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation.Pulsed Erlotinib as Sole Treatment of Leptomeningeal Carcinomatosis: Can We Avoid the Use of Intrathecal Therapy?Whole brain radiotherapy in management of non-small-cell lung carcinoma associated leptomeningeal carcinomatosis: evaluation of prognostic factors.Chemical meningitis related to intra-CSF liposomal cytarabine.Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR.Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments.EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours†Non-small cell lung cancer leptomeningeal metastases treated with intrathecal therapy plus osimertinib and temozolomide and whole-brain radiation therapy: a case report
P2860
Q26741320-F5CA7094-6799-4D0B-839C-B9D866004138Q26781690-4E59231D-36A7-4F26-921F-048430EEC8BCQ28082294-B501371B-1E37-488B-AEE1-61A439E7CC96Q33653615-4271F412-4830-4737-898D-25B086B1256FQ33760992-625ABE9D-F2DF-4BFC-AAA0-E43365875096Q34772704-D944775D-D651-4DD0-85FB-14AC603D32D1Q35057308-E463596D-A182-455C-81B4-7B88946ECA17Q35776489-2B0D1DD6-F92C-435E-BFEF-3E600F800B04Q36550838-C5F31B35-E5B6-4F6A-AD61-1DAD74467A41Q37107954-F8C2F829-4141-4595-BC21-C6EDCA66E742Q37355963-E61E93B3-371E-4BB8-A042-CAEE7EFCCAE8Q38575289-72BAF8BE-9644-4CF5-AD00-BCDB57D16EEBQ38816270-24B1857E-F42C-401A-884E-7100A67120E8Q38985340-63ACF659-376D-40CA-91ED-7645363D7262Q39126729-EF0BF5A1-3AC5-4F8D-A93F-F49C939F316EQ39126735-187292D2-9F29-4262-A274-67D2D689F02EQ39556310-39C1520D-94EA-49D9-B209-126FCE677D6CQ40835500-4FAB4A22-5C3F-4E36-9179-85DFE6E614A0Q42668078-BCCF8421-F622-4593-9EF4-3F8BC4EA861EQ44434925-39018E6A-FC85-4EE1-A613-5A02E4E95A53Q48675213-9E046C83-45AB-4DFE-B66C-CBABFA2F02A0Q50066702-5B8FF7CF-E8A2-46C6-98A5-E785F8EE545EQ54989107-5931B9DA-D953-4268-8227-4D590A4E2AAAQ55327976-C032DA5E-69C9-4C6E-BDA9-666ABCBA8D45Q57578829-B79BCB4D-D075-4883-82C0-1FCB803531AFQ58790306-B2240C89-6965-4B4B-9018-CAF5D62A23D3
P2860
Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Leptomeningeal carcinomatosis ...... correlated prognostic factors.
@en
Leptomeningeal carcinomatosis ...... correlated prognostic factors.
@nl
type
label
Leptomeningeal carcinomatosis ...... correlated prognostic factors.
@en
Leptomeningeal carcinomatosis ...... correlated prognostic factors.
@nl
prefLabel
Leptomeningeal carcinomatosis ...... correlated prognostic factors.
@en
Leptomeningeal carcinomatosis ...... correlated prognostic factors.
@nl
P2093
P1476
Leptomeningeal carcinomatosis ...... correlated prognostic factors.
@en
P2093
Do-Hyun Nam
Jin Seok Ahn
Jong-Mu Sun
Jung Ho Han
Jung-Il Lee
Keunchil Park
Myung-Ju Ahn
Su Jin Lee
Young Chan Ahn
P304
P356
10.1097/JTO.0B013E3182773F21
P577
2013-02-01T00:00:00Z